One of them was linked to the overexpression of ABCG2 and ABCB1, granting multiple drug resistance to CSC; however, pre-treatment with DAPT significantly reduced cisplatin-mediated enrichment of drug-resistant CD133+ cells in NSCLC xenografts [186]. This evidence concerns the gene PROM1 and non-small cell lung carcinoma.